We are live on ! Find out more
ELI

ELITE PHARMACEUTICAL
ELI

Delisted

ELI was delisted on the 20th of May, 2009.

Back to rankings

3 hedge funds and large institutions have $94.3K invested in ELITE PHARMACEUTICAL in 2017 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

41% more capital invested

Capital invested by funds: $66.9K → $94.3K (+$27.4K)

0% more funds holding

Funds holding: 3 → 3 (0)

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GA
Geneva Advisors
Illinois
+$9.01K

Top Sellers

No sellers this quarter

ELI Hedge Fund Activity: Q2 2017 in Review

3 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q2 2017, worth a combined $94.3K — up 41% from $66.9K a quarter earlier.

Fund positioning in ELI was balanced in Q2 2017: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was Geneva Advisors, adding an estimated $9.01K.

  • 3 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q2 2017, unchanged from Q1 2017.
  • Funds reported $94.3K of ELITE PHARMACEUTICAL stock for Q2 2017, up 41% quarter-over-quarter.
  • 0 funds opened new ELITE PHARMACEUTICAL positions in Q2 2017 and 0 closed out.
  • The largest ELITE PHARMACEUTICAL buyer in Q2 2017 was Geneva Advisors, an estimated $9.01K added.

Based on aggregated 13F filings for Q2 2017.